PMID- 32689848
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 2058-7384 (Electronic)
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 34
DP  - 2020 Jan-Dec
TI  - Evolution of our view on the IgE molecule role in bronchial asthma and the 
      clinical effect of its modulation by omalizumab: Where do we stand today?
PG  - 2058738420942386
LID - 10.1177/2058738420942386 [doi]
LID - 2058738420942386
AB  - Bronchial asthma is a heterogeneous disease whose definition and treatment are 
      based on evidence of variable airway obstruction and airway inflammation. Despite 
      the enormous increase in the amount of information on the pathogenesis of this 
      disease, diagnosis is still an unresolved problem, as we still lack sensitive and 
      specific biomarkers. On the other hand, at the turn of the 20th and 21st century, 
      there was a rapid development of therapeutic modalities based on the principle of 
      biological therapy. The first authorized drug matching these characteristics was 
      omalizumab - a monoclonal antibody directed against immunoglobulin E (IgE). It 
      has been used for the treatment of severe forms of bronchial asthma for more than 
      15 years, which is a sufficient time to acquire ways of its effective use and to 
      assess whether the treatment with omalizumab has met our expectations. However, 
      we continue to discover new and surprising facts about the effects of omalizumab 
      treatment which leads to widening of therapeutic indications. In this work, a 
      basic overview of the very complex role of the IgE molecule in the organism (with 
      a special emphasis on allergic asthma) is discussed, and the most important 
      practical and clinical consequences resulting from its modulation by targeted 
      therapy with omalizumab are summarized.
FAU - Novosad, Jakub
AU  - Novosad J
AUID- ORCID: 0000-0003-3290-3821
AD  - Institute of Clinical Immunology and Allergology, University Hospital Hradec 
      Kralove, Hradec Kralove, Czech Republic.
AD  - Faculty of Medicine in Hradec Kralove, Charles University in Prague, Prague, 
      Czech Republic.
FAU - Krcmova, Irena
AU  - Krcmova I
AD  - Institute of Clinical Immunology and Allergology, University Hospital Hradec 
      Kralove, Hradec Kralove, Czech Republic.
AD  - Faculty of Medicine in Hradec Kralove, Charles University in Prague, Prague, 
      Czech Republic.
LA  - eng
PT  - Letter
PT  - Review
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/adverse effects/*therapeutic use
MH  - Anti-Asthmatic Agents/adverse effects/*therapeutic use
MH  - Asthma/diagnosis/*drug therapy/immunology/physiopathology
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Lung/*drug effects/immunology/physiopathology
MH  - Molecular Targeted Therapy
MH  - Omalizumab/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC7375718
OTO - NOTNLM
OT  - IgE receptors
OT  - biological therapy
OT  - immunoglobulin E
OT  - omalizumab
COIS- Declaration of conflicting interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/07/22 06:00
MHDA- 2021/06/03 06:00
PMCR- 2020/07/20
CRDT- 2020/07/22 06:00
PHST- 2020/07/22 06:00 [entrez]
PHST- 2020/07/22 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/07/20 00:00 [pmc-release]
AID - 10.1177_2058738420942386 [pii]
AID - 10.1177/2058738420942386 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420942386. doi: 
      10.1177/2058738420942386.